Biphenyl

Biphenyl

SCHEMBL505047

O=C(Cl)c1ccccc1.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.52
KMO O15229 1/20 0.52
NPC1 O15118 1/20 0.52
CTDSP1 Q9GZU7 1/20 0.52
MAPT P10636 4/20 0.50
ALDH1A1 P00352 3/20 0.50
CES2 O00748 3/20 0.50
CES1 P23141 3/20 0.50
TSHR P16473 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
DAO P14920 1/20 0.50
NAPRT Q6XQN6 1/20 0.50
HDAC8 Q9BY41 1/20 0.47
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 1/20 0.46
GSK3B P49841 2/20 0.46
TRPA1 O75762 1/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14416 0.92 SMN1; SMN2 (0.60) RAB9ANPC1CTDSP1MAPTALDH1A1
Biphenyl SCHEMBL28809192 0.92 SMN1; SMN2 (0.60) RAB9ANPC1CTDSP1MAPTALDH1A1
SCHEMBL9452041 0.92 SMN1; SMN2 (0.60) RAB9ANPC1CTDSP1MAPTALDH1A1
SCHEMBL8723556 0.92 SMN1; SMN2 (0.60) RAB9ANPC1CTDSP1MAPTALDH1A1
Benzoyl Chloride SCHEMBL1241 0.92
Benzoyl Chloride SCHEMBL8995857 0.92 CES1 (0.58) MAPTALDH1A1CES2CES1TSHR
SCHEMBL19185622 0.92 CES1 (0.58) MAPTALDH1A1CES2CES1TSHR
Benzoyl Chloride SCHEMBL1331834 0.92
Benzoyl Chloride SCHEMBL14359354 0.92 CES1 (0.58) MAPTALDH1A1CES2CES1TSHR
Biphenyl SCHEMBL8775397 0.90 SMN1; SMN2 (0.58) RAB9ANPC1CTDSP1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834392-B2 KDM4B inhibitors for the treatment of inflammatory diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2023-12-05 US disclosed
US-20220119344-A1 KDM4B INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT D/B/A ZUCKER INSTITUTE FOR INNOVATION COMMERCIALIZATION 2022-04-21 US disclosed
WO-2020247567-A1 KDM4B INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2020-12-10 WO disclosed
US-9006454-B2 Dihydroorotate dehydrogenase inhibitors MERCK SERONO S.A. (CH) 2015-04-14 US disclosed
EP-2414328-A2 DIHYDROOROTATE DEHYDROGENASE INHIBITORS Merck Serono S.A. (CH) 2012-02-08 EP disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 US disclosed
WO-2010115736-A2 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, FH, DPYD RAB9A 1436/4885KMO 570/4885NPC1 3171/4885
US-20220119344-A1 KDM4B INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS KDM1B, KDM4B, KDM3B RAB9A 3196/4885KMO 1354/4885NPC1 3175/4885
US-11834392-B2 KDM4B inhibitors for the treatment of inflammatory diseases and disorders KDM1B, KDM4B, KDM3B RAB9A 3196/4885KMO 1354/4885NPC1 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.